Mymetics is focused on several pathways to develop prophylactic vaccines and immunotherapies with virosomes:
- The ability to build a first line of defence against viruses entering the blood stream by focusing on the mucosal layer and generating mucosal and serum antibodies
- Improve the working of the immune system through generation of specific CD4+ and CD8+ T cells, especially needed for oncology immunotherapies
- The development of a thermostable and cold chain virosome vaccine formulations that can be administered through intra-nasal, sub lingual or oral routes.
Using these pathways, our pipeline comprises vaccine candidates at various stages of clinical development under our own development or in collaboration with partners.
INFLUENZA and RSV
Two highly contagious viruses, with a high prevalence in developed countries, causing respiratory tract infections in patients of all ages. While seasonal Flu vaccines, efficacy can be improved and longer and broader protection is sought after. For RSV, there is currently no approved vaccine available.
HIV / AIDS
With over 35 million victims, it is the fourth cause of mortality worldwide. Mymetic's HIV vaccine is the first with a demonstrated ability to prevent viral transmission in primates.
Malaria
Malaria is an entirely preventable and treatable mosquito-borne illness, but still caused 435,000 deaths in 2017… we are developing a transmission blocking malaria vaccine.
IMMUNOTHERAPY
New oncology immunotherapies, especially in the field of check point blockade / inhibitors, have provided significant progress in the treatment of certain cancers. Besides the proven safety and immunogenicity track record of virosome vaccines to generate antibodies, Mymetics’ virosomes are known to be able to trigger CD4+ and also CD8+ T cells through MHC-I presentation, providing an excellent platform to improve cancer immune therapies.
Chikungunya
Chikungunya virus (CHIKV) is transmitted by several species of mosquitos, which also are known to transmit Yellow Fever, Dengue and Zika. Symptoms of Chikungunya include joint pain, swelling and stiffness of the joints, headache, fatigue, nausea, rash and fever. Arthritis is the most common direct consequence of infection.